Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$68.98 -3.6%	$62.63	$43.70 ▼ $86.53	$2.28B	-1.49	45,953 shs	104,715 shs
CNTA Centessa Pharmaceuticals	$17.64 +2.9%	$14.64	$9.60 ▼ $19.09	$2.30B	1.48	1.12 million shs	890,003 shs
IRON Disc Medicine	$60.72 -0.6%	$55.99	$30.82 ▼ $68.73	$2.12B	0.77	389,824 shs	443,793 shs
SIGA Siga Technologies	$8.58 -2.3%	$6.91	$4.95 ▼ $11.91	$628.70M	0.94	581,263 shs	507,609 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-3.61%	-1.58%	+8.94%	+7.11%	+38.24%
CNTA Centessa Pharmaceuticals	+2.92%	+2.68%	+16.98%	+41.01%	+40.00%
IRON Disc Medicine	-0.62%	+6.40%	+7.91%	+26.26%	+34.01%
SIGA Siga Technologies	-2.28%	+0.35%	+28.06%	+43.24%	-28.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.7327 of 5 stars	3.5	4.0	2.2	0.8	0.6
CNTA Centessa Pharmaceuticals	2.6524 of 5 stars	3.5	1.0	2.4	3.3	0.6
IRON Disc Medicine	3.2575 of 5 stars	4.5	3.0	1.6	2.5	0.0
SIGA Siga Technologies	2.0791 of 5 stars	0.0	2.0	2.5	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	40.14% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	59.30% Upside
IRON Disc Medicine	3.08	Buy	$95.73	57.65% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SIGA, IRON, BLTE, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00
7/3/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.71 per share	N/A
CNTA Centessa Pharmaceuticals	$6.85M	345.25	N/A	N/A	$2.57 per share	6.86
IRON Disc Medicine	N/A	N/A	N/A	N/A	$17.73 per share	N/A
SIGA Siga Technologies	$138.72M	4.43	$0.82 per share	10.49	$2.92 per share	2.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.55	N/A	N/A	N/A	N/A	-34.90%	-33.56%	N/A
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	N/A
IRON Disc Medicine	-$109.36M	-$4.47	N/A	N/A	N/A	N/A	-26.60%	-24.58%	N/A
SIGA Siga Technologies	$59.21M	$1.13	7.59	6.86	N/A	45.73%	40.52%	35.62%	N/A

Latest SIGA, IRON, BLTE, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/11/2025	Q2 2025	BLTE Belite Bio	-$0.47	-$0.50	-$0.03	-$0.50	N/A	N/A
8/7/2025	Q2 2025	IRON Disc Medicine	-$1.17	-$1.58	-$0.41	-$1.58	N/A	N/A
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	23.15	24.31
CNTA Centessa Pharmaceuticals	0.32	10.11	14.37
IRON Disc Medicine	0.05	32.11	37.65
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CNTA Centessa Pharmaceuticals	82.01%
IRON Disc Medicine	83.70%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CNTA Centessa Pharmaceuticals	7.09%
IRON Disc Medicine	3.64%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
CNTA Centessa Pharmaceuticals	200	134.07 million	124.15 million	Optionable
IRON Disc Medicine	30	34.63 million	33.37 million	Not Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

SIGA, IRON, BLTE, and CNTA Headlines

Recent News About These Companies

Siga Technologies (NASDAQ:SIGA) Rating Increased to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

August 7, 2025 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Royce & Associates LP Has $4.16 Million Holdings in Siga Technologies Inc. (NASDAQ:SIGA)

July 28, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 24, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

New nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactors

June 25, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SIGA, IRON, BLTE, and CNTA Company Descriptions

Belite Bio NASDAQ:BLTE

$68.98 -2.58 (-3.61%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$69.07 +0.09 (+0.13%)

As of 08/14/2025 04:10 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Centessa Pharmaceuticals NASDAQ:CNTA

$17.64 +0.50 (+2.92%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$17.57 -0.07 (-0.40%)

As of 08/14/2025 05:02 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Disc Medicine NASDAQ:IRON

$60.72 -0.38 (-0.62%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$60.75 +0.03 (+0.05%)

As of 04:25 AM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Siga Technologies NASDAQ:SIGA

$8.58 -0.20 (-2.28%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$8.58 0.00 (0.00%)

As of 04:05 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time